Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.55 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2832488 | 0.91 | FFAR2 (0.52) | KCNH2SPHK1SPHK2NR4A2TNKS2 | |
| SCHEMBL2713220 | 0.87 | KCNH2 (0.55) | KCNH2SPHK1SPHK2NR4A2MAOB | |
| SCHEMBL2714652 | 0.87 | KCNH2 (0.55) | KCNH2SPHK1SPHK2NR4A2MAOB | |
| SCHEMBL2712695 | 0.87 | KCNH2 (0.55) | KCNH2SPHK1SPHK2NR4A2MAOB | |
| SCHEMBL12973314 | 0.87 | KCNH2 (0.51) | KCNH2SPHK1SPHK2POLBMAOB | |
| SCHEMBL483601 | 0.80 | KCNH2 (0.51) | KCNH2SPHK1SPHK2NR4A2POLB | |
| SCHEMBL483469 | 0.80 | KCNH2 (0.51) | KCNH2SPHK1SPHK2NR4A2POLB | |
| SCHEMBL20835720 | 0.79 | FFAR2 (0.42) | KCNH2FFAR2 | |
| SCHEMBL4710269 | 0.78 | FFAR2 (0.51) | SPHK1SPHK2TNKS2FFAR2NPC1 | |
| SCHEMBL4637674 | 0.78 | FFAR2 (0.51) | SPHK1SPHK2TNKS2FFAR2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855218-B2 | (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide; depression or a mood disorder ; modulation of use-dependent voltage-gated sodium channels | Convergence Pharmaceuticals Limited (GB) | 2010-12-21 | — | — | US | disclosed |
| EP-1943216-B1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LTD (GB) | 2010-06-30 | — | — | EP | disclosed |
| US-20080306122-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-12-11 | — | — | US | disclosed |
| EP-1943216-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007042250-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306122-A1 | Novel Compounds | CYP11B1, CYP11B2, CYP46A1 | KCNH2 3313/4885SPHK1 726/4885SPHK2 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.